DDW: Oral JAK Inhibitor Hits Snag in Crohn’s Disease (CME/CE)
CHICAGO (MedPage Today) — Phase II trials of an investigational oral Janus kinase inhibitor called tofacitinib in Crohn’s disease and ulcerative colitis yielded mixed results, a researcher reported here, indicating that the conditions really are different entities.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com